Inactive Instrument

Analyst Reco. Axovant Sciences Ltd Nyse

Equities

HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	28/04/22	MT
Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	28/04/22	MT
Cantor Adjusts Sio Gene Therapies Price Target to $3 From $8, Maintains Overweight Rating	01/02/22	MT
HC Wainwright Adjusts Price Target on Sio Gene Therapies to $7 From $10, Reiterates Buy Rating	01/02/22	MT
SVB Leerink Downgrades Sio Gene Therapies to Market Perform From Outperform, Adjusts Price Target to $1 From $6	01/02/22	MT
SIO GENE THERAPIES : HC Wainwright Adjusts Sio Gene Therapies PT to $10 From $8, Maintains Buy Rating	21/10/21	MT
SIO GENE THERAPIES : BTIG Starts Sio Gene Therapies at Buy With $8 Price Target	15/06/21	MT
SIO GENE THERAPIES : SVB Leerink Adjusts Sio Gene Therapies' Price Target to $8 From $7, Keeps at Outperform	16/12/20	MT

No results for this search